Publication Name	World Journal of Clinical Oncology
Manuscript ID	42977
Country	France

Category	Oncology
Manuscript Type	Retrospective Cohort Study
Article Title	Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
Manuscript Source	Unsolicited Manuscript
All Author List	Madeline Devaux, Laura Gerard, Corentin Richard, Leila Bengrine-Lefevre, Julie Vincent, Antonin Schmitt and François Ghiringhelli
Funding Agency and Grant Number
Corresponding Author	François Ghiringhelli, MD, Attending Doctor, Doctor, Professor, Department of Medical Oncology, Centre George François Leclerc, 1 Rue du Professeur Marion, Dijon 21000, France. fghiringhelli@cgfl.fr
Key Words	Colorectal cancer; Chemotherapy; Irinotecan; Second-line; Aflibercept
Core Tip	This retrospective study suggests that modified FOLFIRI with injection of irinotecan at day 1 and 3 is interesting for patients with previously treated metastatic colorectal cancer. Surprisingly the efficacy of the FOLFIRI3-aflibercept seems superior the FOLFIRI3 alone or in combination with bevacizumab. Prospective randomized trial comparing FOLFIRI-aflibercept to FOLFIRI3-aflibercept in second line are warranted.
Citation	Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F. Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World J Clin Oncol 2019; 10(2): 75-85

Received	2018-10-17 02:48
Peer-Review Started	2018-10-17 08:52
To Make the First Decision	2018-11-29 07:40
Return for Revision	2018-11-30 02:42
Revised	2018-12-31 12:38
Second Decision	2019-01-16 08:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-01-23 17:31
Articles in Press	2019-01-23 17:31
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-02-21 09:34

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com